AI Article Synopsis
- * Blocking SGLT1 can lower blood sugar levels and potentially protect the heart by reducing harmful substances, but it also comes with risks like diarrhea and complications in managing low blood sugar.
- * Overall, inhibiting SGLT1 presents both benefits and drawbacks, making it a complex strategy in diabetes management that needs careful consideration.
Article Abstract
Sodium Glucose Cotransporters 1 (SGLT1) play important roles in the intestinal absorption of glucose and the renal reabsorption of glucose, especially in patients with uncontrolled diabetes and those receiving SGLT2 inhibitors. As a consequence, the inhibition of SGLT1 transporters may represent an interesting therapeutic option in patients with diabetes. However, genetic models of SGLT1 inactivation indicate that the malfunction of these transporters may have adverse effects on various tissues. In this review, we discuss the available evidence on the beneficial and detrimental effects that the inhibition of SGLT1 transporters might have. The inhibition of SGLT1 lowers serum glucose levels through the inhibition of intestinal absorption and renal reabsorption of glucose. In addition, drugs that interfere with SGLT1-mediated transport of glucose may protect cardiac tissue by reducing glycogen accumulation and decreasing the production of reactive oxygen species. On the other hand, this strategy may result in diarrhea, volume depletion, may interfere with the correction of hypoglycemia through the oral administration of carbohydrates and could predispose to the development of euglycemic diabetic ketoacidosis. Therefore, at the moment, SGLT1 inhibition seems to represent a two-edged sword.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejphar.2018.09.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance.
Cardiovasc Res
December 2024
Translational Cardiovascular Medicine UR 3074, FMTS, 1 rue Eugène Boeckel, Strasbourg 67084, France.
Aims: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) show a cardioprotective effect in heart failure and myocardial infarction, pathologies often associated with low-grade inflammation. This cross-sectional study aims to investigate whether low-grade inflammation regulates SGLT2 expression and function in human vasculature, heart, and endothelial cells (ECs).
Methods And Results: Human internal thoracic artery (ITA), left ventricle (LV) specimens, and cultured porcine coronary artery ECs were used.
SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms.
Front Cardiovasc Med
December 2024
Department of Cardiology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors afford significant cardiovascular benefits to patients with diabetes mellitus and heart failure. Three large randomized clinical trials (EMPAREG-Outcomes, DECLARE-TIMI58, and DAPA-HF) have shown that SGLT2 inhibitors prevent cardiovascular events and reduce the risk of death and hospital admission resulting from heart failure. Patients without type 2 diabetes mellitus (T2DM) also experience a similar degree of cardiovascular benefit as those with T2DM do.
View Article and Find Full Text PDFTranscriptomics of SGLT2-positive early proximal tubule segments in mice: response to type 1 diabetes, SGLT1/2 inhibition, or GLP1 receptor agonism.
Am J Physiol Renal Physiol
January 2025
Division of Nephrology & Hypertension, Department of Medicine, University of California San Diego, La Jolla, California, United States.
SGLT2 inhibitors (SGLT2i) and GLP1 receptor (GLP1R) agonists have kidney protective effects. To better understand their molecular effects, RNA sequencing was performed in SGLT2-positive proximal tubule segments isolated by immunostaining-guided laser capture microdissection. Male adult DBA wild-type (WT) and littermate diabetic Akita mice ± knockout (-KO) were given vehicle or SGLT2i dapagliflozin (dapa; 10 mg/kg diet) for 2 wk, and other Akita mice received GLP1R agonist semaglutide [sema; 3 nmol/(kg body wt·day), sc].
View Article and Find Full Text PDFSodium-dependent glucose co-transport proteins (SGLTs) are not involved in human glucose taste detection.
PLoS One
November 2024
The Coca-Cola Company, Atlanta, Georgia, United States of America.
The sweet taste of saccharides, such as sucrose and glucose, and other sweeteners is known to result from activation of the TAS1R2/R3 receptor expressed in taste receptor cells (TRCs) of the taste bud. Recent reports have suggested the existence of an additional sweet taste signaling pathway for metabolizable saccharides that is dependent on the activity of glucose transporters, especially SGLT1, also expressed in TRCs. We have investigated the potential contribution of SGLT1 to glucose taste signaling in humans.
View Article and Find Full Text PDFThe Impact of SGLT1 Inhibition on Frailty and Sarcopenia: A Mediation Mendelian Randomization Study.
J Cachexia Sarcopenia Muscle
December 2024
Department of Geriatrics, First Affiliated Hospital of Fujian Medical University, Institute of Neuroscience, Fujian Medical University, Fuzhou, China.
Article Synopsis
- The study explored the effect of inhibiting SGLT1 on frailty and sarcopenia in older adults, aiming to understand its potential benefits.
- A two-sample Mendelian randomization analysis showed that SGLT1 inhibition led to a decrease in frailty index and a lower risk of weak grip strength in individuals aged 60 and over.
- Findings identified insulin resistance and various proteins and metabolites as mediators, suggesting that targeting SGLT1 could be a promising therapeutic approach for improving health in older adults.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!